TY - JOUR
T1 - Structure and function of an effector domain in antiviral factors and tumor suppressors SAMD9 and SAMD9L
AU - Peng, Shuxia
AU - Meng, Xiangzhi
AU - Zhang, Fushun
AU - Pathak, Prabhat Kumar
AU - Chaturvedi, Juhi
AU - Coronado, Jaime
AU - Morales, Marisol
AU - Mao, Yuanhui
AU - Qian, Shu Bing
AU - Deng, Junpeng
AU - Xiang, Yan
N1 - Publisher Copyright:
© 2022 National Academy of Sciences. All rights reserved.
PY - 2022/1/25
Y1 - 2022/1/25
N2 - SAMD9 and SAMD9L (SAMD9/9L) are antiviral factors and tumor suppressors, playing a critical role in innate immune defense against poxviruses and the development of myeloid tumors. SAMD9/9L mutations with a gain-of-function (GoF) in inhibiting cell growth cause multisystem developmental disorders including many pediatric myelodysplastic syndromes. Predicted to be multidomain proteins with an architecture like that of the NOD-like receptors, SAMD9/9L molecular functions and domain structures are largely unknown. Here, we identified a SAMD9/9L effector domain that functions by binding to double-stranded nucleic acids (dsNA) and determined the crystal structure of the domain in complex with DNA. Aided with precise mutations that differentially perturb dsNA binding, we demonstrated that the antiviral and antiproliferative functions of the wild-type and GoF SAMD9/9L variants rely on dsNA binding by the effector domain. Furthermore, we showed that GoF variants inhibit global protein synthesis, reduce translation elongation, and induce proteotoxic stress response, which all require dsNA binding by the effector domain. The identification of the structure and function of a SAMD9/9L effector domain provides a therapeutic target for SAMD9/9Lassociated human diseases.
AB - SAMD9 and SAMD9L (SAMD9/9L) are antiviral factors and tumor suppressors, playing a critical role in innate immune defense against poxviruses and the development of myeloid tumors. SAMD9/9L mutations with a gain-of-function (GoF) in inhibiting cell growth cause multisystem developmental disorders including many pediatric myelodysplastic syndromes. Predicted to be multidomain proteins with an architecture like that of the NOD-like receptors, SAMD9/9L molecular functions and domain structures are largely unknown. Here, we identified a SAMD9/9L effector domain that functions by binding to double-stranded nucleic acids (dsNA) and determined the crystal structure of the domain in complex with DNA. Aided with precise mutations that differentially perturb dsNA binding, we demonstrated that the antiviral and antiproliferative functions of the wild-type and GoF SAMD9/9L variants rely on dsNA binding by the effector domain. Furthermore, we showed that GoF variants inhibit global protein synthesis, reduce translation elongation, and induce proteotoxic stress response, which all require dsNA binding by the effector domain. The identification of the structure and function of a SAMD9/9L effector domain provides a therapeutic target for SAMD9/9Lassociated human diseases.
KW - Innate immunity
KW - Myelodysplasia syndrome
KW - Myeloid malignancies
KW - NOD
KW - Poxvirus
UR - http://www.scopus.com/inward/record.url?scp=85123125262&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123125262&partnerID=8YFLogxK
U2 - 10.1073/pnas.2116550119
DO - 10.1073/pnas.2116550119
M3 - Article
C2 - 35046037
AN - SCOPUS:85123125262
SN - 0027-8424
VL - 119
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
IS - 4
M1 - e2116550119
ER -